Previous close | 19.12 |
Open | 19.16 |
Bid | 19.37 x 900 |
Ask | 19.48 x 800 |
Day's range | 19.14 - 19.42 |
52-week range | 12.40 - 19.43 |
Volume | |
Avg. volume | 931,318 |
Market cap | 3.13B |
Beta (5Y monthly) | 1.32 |
PE ratio (TTM) | 8.35 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.92 (9.95%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
SAN MATEO, Calif., April 30, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a first quarter 2024 total cash distribution of $0.48 per share. The following shows the key dates of the first quarter 2024 dis
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, today announces it has entered into a $35m loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules").
SAN MATEO, Calif., April 24, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), is celebrating its 20th year of originations activity by reaching the $20.0 billion milestone in total debt commitments.